Interleukin enhancer-binding factor 3 (ILF3) and ILF2 (also named NF45) were originally discovered as positive regulators of IL2 transcription as part of the NFAT-AP1-NF-kB enhanceosome in activated T-cells and have roles in cancer [157,158,159], autoimmune and inflammatory conditions [160,161], and psychiatric disorders [162]. Here, ILF3 is linked to cancer.